Biological activity of limitin and adiponectin
Biological activity of limitin and adiponectin
批准号:
13671064
负责人:
ORITANI Kenji
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002
中文摘要
点击翻译按钮获取中文摘要
英文摘要
(1) Adiponectin: Adiponectin, one of the major products of adipocytes, strongly inhibited B lymphopoiesis in long-term bane marrow cultures, but only when stromal cells were present. Cox-2 inhibitors abrogated the response of early lymphoid progenitors to adiponectin in stromal cell containing cultures. Furthermore, prostaglandin E2, a major product of Cox-2 activity; had a direct inhibitory influence on purified hematopoietic cells, suggesting a possible mechanism of adiponectin action in culture.(2) Limitin: Limitin, an IFN-like cytokine, augmented the killer activity of cytotoxic T lymphocytes as well as the surface expression of MHC class I molecules. Limitin inhibited the proliferation of FDCP-1 cells stably transfected with p210bcr/abl. Limitin also induced antiviral state against EMCV, MHV, and HSV. Although the above functions of limitin were similar to those of IFN-α, higher concentration of limitin was required than IFN-α for the inhibition of CFU-IL7 or CFU-Meg colony formation. Limitin could not inhibit CFU-GM or BFU-E colony formation while IFN-α did. These data suggest that limitin may be less toxic than other IFNs, and therefore may have a unique clinical niche for treatment of diseases where type I IFNs have proven useful. In signals for IFN-mediated myelosuppression, the disruption of Tyk2 completely abrogated IFN-α-induced inhibition of CFU-IL7 and CFU-Meg colony formation. We are now analyzing the difference of downstream signals of Tyk2 between limitin and IFN-α.Immunohistochemical analysis revealed that the limitin protein is constitutively produced by mature T lymphocytes in spleen and thymus. Unlikely other IFNs, limitin expression was not up-regulated by virus-infection. These data may suggest that limitin acts to avoid virus-infection or to eliminate harmful cells in healthy conditions.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Yokota T: "Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins"J Clin Invest. 109. 1303-1310 (2002)
Yokota T:“通过脂联素和前列腺素对骨髓培养物中脂肪细胞形成的旁分泌调节”J Clin Invest。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yoshida H et al.: "Interaction between SHPS-1 and CD47 mediates the adhesion of human B lymphocytes to non activated endothelial cells"J Immunol. (in peess).
Yoshida H 等人:“SHPS-1 和 CD47 之间的相互作用介导人 B 淋巴细胞与非活化内皮细胞的粘附”JImmunol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yokota T et al.: "Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins."J Clin Invest. 109. 1303-1310 (2002)
Yokota T 等人:“通过脂联素和前列腺素对骨髓培养物中脂肪细胞形成进行旁分泌调节。”J Clin Invest。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Shimoda K: "Cutting edge : tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation"J Immunol. 169. 4707-4711 (2002)
Shimoda K:“最前沿:tyk2 是 Daxx 的诱导和核转位所必需的,Daxx 调节 IFN-α 诱导的 B 淋巴细胞形成抑制”JImmunol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kouro T, et al: "Characteristics of early murine B-lymphocyte precursors and their direct sensitivity to negative regulators."Blood. 97. 2708-2715 (2001)
Kouro T 等人:“早期鼠 B 淋巴细胞前体的特征及其对负调节因子的直接敏感性。”血液。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 21 条
Analysis of in vivo effects of possible immune regulatory moleculesfor artificial management of immune systems
-
批准号:22591062
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2010
-
负责人:ORITANI Kenji
-
依托单位:
Development of a novel interferon with mild adverse effects
-
批准号:19390264
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.98万
-
财政年份:2007
-
负责人:ORITANI Kenji
-
依托单位:
Establishment of a novel IFN therapy with little side effects
-
批准号:17390277
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.86万
-
财政年份:2005
-
负责人:ORITANI Kenji
-
依托单位:
Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
-
批准号:15390300
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.47万
-
财政年份:2003
-
负责人:ORITANI Kenji
-
依托单位:
Clinical application of limitin that has anti-tumor and anti-viral activity
-
批准号:13557081
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.9万
-
财政年份:2001
-
负责人:ORITANI Kenji
-
依托单位:
海外基金